References: 1. Moreno L, Linossi C, Esteban I, et al. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin Transl Oncol. 2016;18(10):981-987. 2. National Institutes of Health. National Cancer Institute. BRCA mutations: cancer risk and genetic testing. What are BRCA1 and BRCA2? National Institutes of Health Web site. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q5. Accessed May 10, 2018. 3. Levin B, Lech D, Friedenson B. Evidence that BRCA1- or BRCA2-associated cancers are not inevitable. Mol Med. 2012;18(1)1327-1337. 4. Breastcancer.org. Study estimates breast cancer risk by age for women with BRCA mutations. Breastcancer.org Web site. http://www.breastcancer.org/research-news/risk-estimates-by-age-for-brca-mutations. Accessed May 29, 2018. 5. Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1) doi:10.15761/ICST.1000228. 6. Meynard G, Villanueva C, Thiery-Vuillemin A, et al. 284P—Real-life study of BRCA genetic screening in metastatic breast cancer. Ann Oncol. 2017;28(suppl 5):v74-v108. 7. Fasching PA, Hu C, Hart SN, et al. Cancer predisposition genes in metastatic breast cancer—association with metastatic pattern, prognosis, patient and tumor characteristics. Paper presented at 40th Annual San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX. Abstract PD1-02. 8. Nelson HD, Fu R, Goddard K, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review To Update the U.S. Preventive Services Task Force Recommendation. Rockville, MD: Agency for Healthcare Research and Quality; December 2013. Evidence Synthesis, No. 101; AHRQ publication 12-05164-EF-1. 9. Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460-1468. 10. Giordano SH. Breast cancer in men. N Engl J Med. 2018;378(24):2311-2320. 11. Arpino G, Pensabene M, Condello C, et al. Tumor characteristics and prognosis in familial breast cancer. BMC Cancer. 2016;16(1):924. 12. Kleibl Z, Kristensen VN. Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast. 2016;28:136-144. 13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast & Ovarian V.2.2019. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed July 30, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 14. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed April 23, 2018. To view the most recent and complete version of the guideline, go online to NCCN.org.